Get Updates & Request a Rep

Give Patients with ALS a Chance
Help Slow the Loss of Physical Function

RADICAVA® (edaravone) is the only FDA-approved treatment option for ALS shown to slow the loss of physical function in a pivotal clinical trial.1,a

aAs measured by total score on the ALS Functional Rating Scale-Revised (ALSFRS-R) in a 24-week study of 137 participants.1 Individual results may vary.


0 + healthcare providers have prescribed RADICAVA®

in the US as of February 20212,b

0 + patients treated with RADICAVA®

in the US as of January 20212,b

0 % of patients have stayed on RADICAVA®

for at least 6 months2,b

Based on data collected from August 2017-April 2019.

bBased on internal data that has not been independently verified.

video screen with play arrow
Hear from a few of the 1400+ ALS experts who have prescribed RADICAVA®

In the pivotal clinical trial for RADICAVA®, there was

arrows pointing to 33% less change in ALSFRS-R scores from baseline vs placebo at 24 weeks in pivotal clinical trials

less change in ALSFRS-R scores from baseline vs placebo at 24 weeks.1

View Trial Results
benefit investigation and enrollment form (BIF) for RADICAVA® (edaravone), an FDA approved treatment option for ALS

Order RADICAVA® for Patients with ALS

Get forms and information for accessing treatment
$0 per infusion copay card for RADICAVA® (edaravone)

$0 Per Infusion for Eligible Patients with Commercial Insurance

Learn about our Out-of-Pocket Assistance Program for patients with commercial insurance


There is a $20,000 maximum program benefit per calendar year per eligibility criteria.

badge that reads Veterans with ALS

RADICAVA® is on the VHA National Formularyc

Learn how veterans with ALS can get started through the VHA

cSubject to National Prior Authorization criteria.

    References:
  1. RADICAVA Prescribing Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; 2018.
  2. Data on file. Mitsubishi Tanabe Pharma America, Inc.
▲ EXPAND▼ COLLAPSE

Important Safety Information

Hypersensitivity Reactions

Radicava® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in Radicava®. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported. Patients should be monitored carefully for hypersensitivity reactions, and if they occur, discontinue Radicava®, treat per standard of care, and monitor until the condition resolves.

Sulfite Allergic Reactions

Radicava® contains sodium bisulfite, and may cause allergic type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown, but occurs more frequently in asthmatic people.

Most Common Adverse Reactions

Most common adverse reactions (at least 10% and greater than placebo) are contusion, gait disturbance, and headache.

Pregnancy

Based on animal data, Radicava® may cause fetal harm.

Geriatric Use

No overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Indication

Radicava® is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Please see full Prescribing Information.

For more information about RADICAVA®, call 1-888-292-0058.